Experimental pancreatic cancer pill helps improve survival in late-stage study

Revolution Medicines' experimental oral drug ⁠helped patients ​with pancreatic cancer live longer and showed an improvement in survival without worsening ​of the disease in a keenly anticipated late-stage trial. Patients who received the once-daily pill, daraxonrasib, showed a median overall survival of 13.2 months compared with 6.7 months ​for ‌those who were given intravenous cytotoxic chemotherapy, the standard ⁠of care, the company said on Monday.